drugset / Trial / NCT02263976
Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of BEA 2180 BR in Healthy Male Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
Main study: To investigate safety, tolerability, pharmacodynamics (PD) and pharmacokinetics (PK) of BEA 2180 BR Sub-study; To investigate whether treatment with 36 μg tiotropium bromide is able to protect of methacholine-induced bronchoconstriction compared to baseline (methacholine challenge at screening).
Timeline
- Start
- 2003-08
- Primary completion
- 2004-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | BEA 2180 BR | Unknown | 2.5 ug | Inhaled |
| Subject | BEA 2180 BR | Unknown | 1600 ug | Inhaled |
| Subject | Tiotropium | Other / unclassified | 36 ug | — |
Indications
No indication recorded.